Close

CAR IVT LNP Products

All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.

Lipid Nanoparticles (LNPs)-Mediated CAR mRNA Delivery

Unlike genetic transformation methods with plasmid or viral vectors, in vitro transcription (IVT)-mediated transient expression of CAR mRNA is safer in cancer immunotherapy. Since the naked mRNA has a short half-life, drug delivery systems such as lipid nanoparticles (LNPs) are necessary to protect mRNA from degradation and enhance cellular uptake. Creative Biolabs has established a CAR IVT platform to support IVT mRNA & LNP manufacturing. We provide full technical support from project design, sequence optimization, and synthesis, to LNP formulation services. Our scientists will encapsulate mRNA with lipids based on specific requirements.

The advantage of the LNP delivery system:

  • Increased mRNA stability
  • Increased delivery efficiency
  • Reduced immunogenicity
  • Flexible customization to improve their properties

LNPs-mediated CAR mRNA delivery to human T cells. (Billingsley, et al., 2020)Fig.1 LNPs-mediated CAR mRNA delivery to human T cells.1

CAR IVT LNP Products and Services

Creative Biolabs proudly offers CAR IVT LNP products and services for mRNA-based CAR therapy research and development. We have a purpose-built LNP delivery system for effective encapsulation of mRNA. Moreover, we have optimized our manufacturing strategy to maximize yields and ensure the efficacy of encapsulation. Our integrated CAR IVT LNP manufacturing workflow streamlines production from gene synthesis to LNP packaging. Our CAR IVT LNP products help save time and streamline your efforts.

For any specific requirements or technological support, please contact us.

Quality Control

To ensure that CAR IVT LNP is properly synthesized and loaded with the intended mRNA, Creative Biolabs will perform standard and customized quality control assays, including:

  • Assessments of mRNA concentration, mRNA sequence, integrity, capping efficiency, polyA analysis, residual contaminant
  • Characterization of LNP encapsulation (particle size, encapsulation efficiency, and stability)

Manufacturing Workflow

Workflow of CAR IVT LNP manufacture. (Creative Biolabs Original)Fig.2 Workflow of CAR IVT LNP manufacture.

Reference

  1. Billingsley, M.M.; et al. Ionizable lipid nanoparticle-mediated mRNA delivery for human CAR T cell engineering. Nano letters. 2020, 20(3): 1578-89.
Key Updates
Newsletter NEWSLETTER

The latest newsletter to introduce the latest breaking information, our site updates, field and other scientific news, important events, and insights from industry leaders

LEARN MORE NEWSLETTER
New Solution NEW SOLUTION

CellRapeutics™ In Vivo Cell Engineering: One-stop in vivo T/B/NK cell and macrophage engineering services covering vectors construction to function verification.

LEARN MORE SOLUTION
NOVEL SOLUTION NOVEL TECHNOLOGY

Silence™ CAR-T Cell: A novel platform to enhance CAR-T cell immunotherapy by combining RNAi technology to suppress genes that may impede CAR functionality.

LEARN MORE NOVEL TECHNOLOGY
NEW TECHNOLOGY NEW SOLUTION

Canine CAR-T Therapy Development: From early target discovery, CAR design and construction, cell culture, and transfection, to in vitro and in vivo function validation.

LEARN MORE SOLUTION
Receive our latest news and insights.